Extended Data Table 5 Most common TEAEs (in ≥20% of patients) by preferred/grouped terms

From: Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

  1. T-DXd, trastuzumab deruxtecan; TEAE, treatment-emergent adverse event; TPC, treatment of physician’s choice of chemotherapy.
  2. aThis category includes the preferred terms fatigue, asthenia, and malaise.
  3. bThis category includes the preferred terms hemoglobin decreased, red blood cell count decreased, anemia, and hematocrit decreased.
  4. cThis category includes the preferred terms neutrophil count decreased and neutropenia.
  5. dThis category includes the preferred terms aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyltransferase increased, and hepatic function abnormal.
  6. eThis category includes the preferred terms back pain, myalgia, pain in extremity, musculoskeletal pain, muscle spasms, bone pain, neck pain, musculoskeletal chest pain, limb discomfort.
  7. fThis category includes preferred terms platelet count decreased and thrombocytopenia.
  8. gThis category includes the preferred terms white blood cell count decreased and leukopenia.
Back to article page